LEO Pharma provides update on the development program for izuforant
- The Phase 2a/b international trial to evaluate the efficacy and safety of orally administered izuforant tablets compared with placebo tablets for up to 16 weeks of treatment in adults with moderate to severe AD did not meet the primary endpoint.
- As a result, LEO Pharma ends the program for izuforant and terminates the license agreement with JW Pharmaceutical.
- LEO Pharma remains committed to delivering value for patients living with atopic dermatitis and other skin diseases.
BALLERUP, Denmark, October 20, 2023 – LEO Pharma today announced the initial headline conclusions from the recently completed Ph2a/b study of izuforant (LEO 152020) in atopic dermatitis (LP0190-1488).
Izuforant – which LEO Pharma has in-licensed in a global agreement with JW Pharmaceutical – was a novel atopic dermatitis drug candidate intended for oral treatment of atopic dermatitis. Izuforant was expected to maximize efficacy by dual action of anti-pruritus (anti-itch) and anti-inflammation and minimize adverse events by high selectivity on the target.
The study – a phase 2 randomized, triple-blind, placebo-controlled, parallel-group, international trial to evaluate the efficacy and safety of orally administered izuforant tablets compared with placebo tablets for up to 16 weeks of treatment in adults with moderate to severe atopic dermatitis did not meet the primary endpoint; i.e. the trial did not demonstrate a statistically significant difference in the mean change from baseline in EASI total score at end of treatment between active treatment arms and placebo.
No new safety issues or concerns were identified.
"At LEO Pharma, we are committed to advancing the standard of care for people living with skin diseases. This also means investing in trials to explore potential new treatments to accommodate the high unmet need these people face every day. But unfortunately, as is the case for all pharmaceutical research, not all trials show the results we hope for," says Kreesten Meldgaard Madsen, Chief Development Officer, LEO Pharma. "While we are disappointed with the outcome for izuforant, which represented a potential new kind of treatment for atopic dermatitis – LEO Pharma remains fully committed to innovative research in atopic dermatitis as we strive to make a difference for people living with skin diseases and their families."
As a result of the study outcome, LEO Pharma has decided to terminate the program and end the licensing agreement with JW Pharmaceutical, who will regain all rights to izuforant
Although this study failed to meet its primary endpoints, the partnership with JW Pharmaceutical is a strong example of LEO Pharma’s commitment to delivering innovation in medical dermatology and reflects LEO Pharma’s research model, which aims at driving the early-stage pipeline through externally sourced innovation, that was announced in early 2023.
--ENDS--
About Izuforant (JW1601)
Izuforant is an orally available histamine H4 receptor inverse agonist with anti-pruritic and anti-inflammatory dual effect. It shows anti-chemotactic activity in eosinophil shape change and therapeutic effect in spontaneous NC/Nga AD model. Izuforant was out-licensed from JW Pharmaceutical to LEO Pharma in 2018.
Kontakter
Henrik Heskjær
Tlf:+45 3140 6180hdtdk@leo-pharma.comJes Broe Frederiksen
Tlf:+45 5360 5948jebfe@leo-pharma.comAbout
About JW Pharmaceutical Corporation
JW Pharmaceutical Corporation has been leading Korean medicine and medical supplies market over its 70 years of history. The company focuses on the field of research and development of anti-cancer drug and etc.; manufacture and sales of hospital fluid, antibiotic and other ethical pharmaceuticals.
JW Pharmaceutical Corporation was founded in 1945 and is listed on the Korea Exchange Market under the symbol "001060".
About LEO Pharma
LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 4,400 people, serving millions of patients across the world. In 2022, the company generated net sales of DKK 10.6 billion.
Følg pressemeddelelser fra LEO Pharma
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra LEO Pharma
LEO Pharma continues global rollout of Anzupgo® (delgocitinib) cream with submission of New Drug Application in China16.10.2025 15:30:00 CEST | Pressemeddelelse
LEO Pharma is seeking to expand the availability of Anzupgo® (delgocitinib) cream to China, as the company announces the submission of a New Drug Application (NDA) to the National Medical Products Administration (NMPA), which has been accepted for review for adult patients with moderate to severe chronic hand eczema. The NDA is supported by results from DELTA China, a phase 3 trial with Anzupgo in Chinese adults with moderate to severe chronic hand eczema (CHE)1 along with the full clinical program of delgocitinib, which includes data from DELTA 1,2 and 3, DELTA Force and DELTA Teen.2-7 The Anzupgo NDA submission demonstrates LEO Pharma's commitment to providing additional treatment options for patients living with skin diseases in China.
LEO Pharma closes deal for Spevigo®1.10.2025 09:00:00 CEST | Pressemeddelelse
Adding Spevigo® is a significant step forward in LEO Pharma’s focused growth strategy, to accelerate and expand patients’ access to treatments for medical dermatological conditions, including generalized pustular psoriasis (GPP), a rare and severe skin condition Spevigo® (spesolimab) is a first-in-class IL-36R antagonist successfully developed and launched by Boehringer Ingelheim and approved globally for the treatment and prevention of GPP flares Spesolimab is also being investigated for the treatment of other IL-36-mediated skin diseases
LEO Pharma Presents Late-Breaking Data at EADV 2025 Showing Week 16 Tralokinumab Response Predicts Long-Term Response in Moderate-to-Severe Atopic Dermatitis19.9.2025 16:00:00 CEST | Pressemeddelelse
Late-breaking data from the ECZTEND trial show that patients with moderate-to-severe atopic dermatitis (AD), who responded to Adtralza® (tralokinumab) / Adbry® (tralokinumab-ldrm) at Week 16, maintained stable, optimal treatment outcomes for up to three years.1 Additional data presented at EADV from the real-world TRACE study further support the long-term use of tralokinumab, with sustained improvements in disease severity, quality of life, sleep, and work productivity observed over 12 months of treatment.2-4 Presented as part of LEO Pharma’s most ambitious scientific program to date at the 2025 EADV Congress, the tralokinumab data reinforce the company’s leadership in medical dermatology and its commitment to advancing innovation across its biologics’ portfolio.
LEO Pharma Presents Late-Breaking Phase 3 Delgocitinib Cream Data in Adolescents with Moderate to Severe Chronic Hand Eczema (CHE)18.9.2025 15:45:00 CEST | Pressemeddelelse
The first late-breaking presentation was the phase 3 trial results for DELTA TEEN, showing delgocitinib cream had superior efficacy compared to cream vehicle and was generally well tolerated in adolescents, aged 12-17, with moderate to severe Chronic Hand Eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate.1 In a second late-breaking presentation, pooled data from five phase 2b and phase 3 trials of delgocitinib cream confirmed a consistent safety profile for the treatment of moderate to severe CHE in adults.2 Fifteen other pieces of delgocitinib cream research formed part of LEO Pharma’s most ambitious scientific program to date at EADV 2025.3-17
LEO Pharma presents two late-breaking abstracts for temtokibart reporting positive Phase 2b efficacy, safety and biomarker results in moderate-to-severe atopic dermatitis at the 2025 EADV Annual Meeting in Paris17.9.2025 16:00:00 CEST | Pressemeddelelse
Results presented at EADV 2025 demonstrated that investigational agent temtokibart met its primary endpoint of percentage change in the Eczema Area and Severity Index (EASI) compared with placebo for the three highest doses (600 mg, 450 mg, and 300 mg).1 Significantly greater improvements in EASI were reported as early as Week 1 for temtokibart 450mg and 300mg, and Week 2 for 600mg, vs placebo; these results were maintained up to Week 32 in 600mg and 300mg arms, despite no treatment after Week 14.1 Safety analyses revealed that temtokibart was well-tolerated with no dose-dependent AEs, a low incidence of conjunctivitis, and no signal for herpes.1
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum